Compare Marvell Technology Inc (MRVL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs GeneDx Holdings Corp — how do they compare? Marvell Technology Inc trades at $275.28 (market cap $246.84B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Marvell Technology Inc is far larger — about 122.2× GeneDx Holdings Corp's market cap, and Marvell Technology Inc pays a 0.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and GeneDx Holdings Corp for 19 Days on average.
| MRVL | WGS | |
|---|---|---|
Market Cap | $246.84B | $2.02B |
Volume | 29,003,830 | 734,640 |
Sector | Technology | Health |
52-Week High | $316.43 | $167.51 |
52-Week Low | $73.73 | $34.51 |
Typical Hold Time | 42 Days | 19 Days |
Enterprise Value | $248.19B | $2.05B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day but maintains strong technical momentum with bullish moving averages and key support at $267. The company shows impressive earnings beats in recent quarters with Q2 2026 EPS of $0.94 beating expectations, while analyst consensus remains overwhelmingly bullish with 84% buy ratings. Recent news highlights Marvell's AI chip growth potential, including a major Google partnership and raised 2028 revenue guidance to $18 billion.
Marvell presents compelling growth prospects driven by AI infrastructure demand and custom chip expansion, though elevated valuation ratios (P/E 90.95, P/S 25.77) warrant caution. Key risks include execution challenges in scaling custom silicon business and competitive pressures in the semiconductor sector. The $327.86 consensus price target suggests 19% upside potential from current levels.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
